Literature DB >> 6120742

Immunoreactive dynorphin in human brain and pituitary.

C Gramsch, V Höllt, A Pasi, P Mehraein, A Herz.   

Abstract

The distribution of immunoreactive dynorphin (ir-dyn) has been determined in various regions of human brain and pituitary by use of a highly specific radioimmunoassay. The concentrations of ir-dyn in the substantia nigra (24.5 pmol/g) and hypothalamus were among the highest in the 26 brain areas examined. Substantial amounts were also measurable in other extrapyramidal structures such as the caudate nucleus, pallidus and putamen. Lower concentrations of ir-dyn were detected in the amygdala, hippocampus, periaqueductal gray matter, colliculi, pons, medulla and area postrema, but only low amounts were found in the posterior lobe of the pituitary, while no ir-dyn was detectable in the anterior lobe. By gel permeation chromatography the brain immunoreactivity was shown to consist of 3-4 peaks of apparent molecular weights of about 12,000, 6000, 1800 and less than 1000. It was possible to demonstrate the high opioid potency of 2 of these peaks in the guinea-pig ileum longitudinal muscle bioassay after purification by immunoprecipitation. A comparison of the distribution pattern of ir-dyn revealed some parallels with enkephalin, whereas the distribution of ir-beta-endorphin is quite different.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6120742     DOI: 10.1016/0006-8993(82)90930-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

Review 1.  Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.

Authors:  V K Shukla; S Lemaire
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

Review 2.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

3.  Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies.

Authors:  I Christensson-Nylander; M Herrera-Marschitz; W Staines; T Hökfelt; L Terenius; U Ungerstedt; C Cuello; W H Oertel; M Goldstein
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

Review 4.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

5.  Generalization tests with intraventricularly applied pro-enkephalin B-derived peptides in rats trained to discriminate the opioid kappa receptor agonist ethylketocyclazocine.

Authors:  G T Shearman; R Schulz; P W Schiller; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action.

Authors:  A I Faden; T P Jacobs
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

7.  Effects of electroacupuncture of different frequencies on the release profile of endogenous opioid peptides in the central nerve system of goats.

Authors:  Li-Li Cheng; Ming-Xing Ding; Cheng Xiong; Min-Yan Zhou; Zheng-Ying Qiu; Qiong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-24       Impact factor: 2.629

Review 8.  General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation.

Authors:  Mun Fei Yam; Yean Chun Loh; Chu Shan Tan; Siti Khadijah Adam; Nizar Abdul Manan; Rusliza Basir
Journal:  Int J Mol Sci       Date:  2018-07-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.